The impact of psoriasis on health care costs and patient work loss - 24/04/13
Abstract |
Background |
There are few comprehensive estimates of the cost of psoriasis in the United States.
Objective |
We sought to quantify the incremental direct medical and indirect work loss costs associated with psoriasis.
Methods |
A de-identified claims database from 31 self-insured employers during the period 1998 to 2005 was used. Patients with at least two psoriasis diagnosis claims (N = 12,280) were compared with 3 control subjects (matched on year of birth and sex) without psoriasis. Multivariate two-part regression analysis was used to isolate the incremental cost of psoriasis by controlling for comorbidities and other confounding factors.
Results |
After multivariate adjustment, the incremental direct and indirect costs of psoriasis were approximately $900 and $600 (P < .001) per patient per year, respectively.
Limitations |
The database used in this study does not contain information on patient out-of-pocket costs or loss of productivity costs at work.
Conclusion |
The incremental cost of psoriasis is approximately $1500 per patient per year, with work loss costs accounting for 40% of the cost burden.
Le texte complet de cet article est disponible en PDF.Abbreviations used : HMO, OTC, PPPM
Plan
Supported by Novartis Pharmaceuticals Corp. |
|
Disclosure: Dr Swensen, Dr Sung, Mr Doyle, and Dr Lobo are employees of and Dr Fowler, Dr Duh, Dr Rovba, Ms Buteau, Ms Pinheiro, Mr Mallett, and Dr Kosicki are consultants to Novartis Pharmaceuticals Corp. |
|
Presented in part at the following poster sessions: 65th Annual Meeting of the American Academy of Dermatology, Washington, DC, February 2-6, 2007, and 12th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Arlington, VA, May 19-23, 2007. |
Vol 59 - N° 5
P. 772-780 - novembre 2008 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?